Searchable abstracts of presentations at key conferences in endocrinology

ea0073oc3.1 | Oral Communications 3: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat is an effective and well-tolerated treatment for Cushing’s Disease (CD): Results from a Phase III, multicentre, randomized, double-blind study with an initial placebo-controlled phase (LINC 4)

Gadelha Monica , MarieBex , Feelders Richard , Heaney Anthony , Auchus Laviola , Gilis-Januszewska Laviola , Witek Przemyslaw , Zhanna Belaya , Zhihong Liao , Chen Ku Witek , Carvalho Davide , Roughton Michael , Wojna Judi , Hofstetter Georg , Pedroncelli Alberto , Snyder Peter

IntroductionOsilodrostat, a potent, oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD during a Phase III, randomized-withdrawal study. We now report findings from a Phase III study of osilodrostat in patients with CD that featured an initial double-blind, randomized, placebo-controlled period (LINC 4; NCT02697734).MethodsAdults with CD (mUFC > 1.3 &...